SCHEMBL14397447

SCHEMBL14397447

C=C(CBr)c1ccc2ccccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.61
HDAC1 Q13547 2/20 0.50
HDAC8 Q9BY41 1/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.47
KDM4E B2RXH2 2/20 0.47
HPGD P15428 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 1/20 0.47
EGFR P00533 1/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
JAK1 P23458 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13089410 0.82 HDAC1 (0.64) PTPN1HDAC1HDAC8CES2CES1
SCHEMBL4196215 0.82 CES2 (0.52) PTPN1HDAC1HDAC8CES2CES1
SCHEMBL16795653 0.82 CES2 (0.52) PTPN1HDAC1HDAC8CES2CES1
SCHEMBL6381436 0.80 SMN1; SMN2 (0.53) PTPN1HDAC1HDAC8CES2CES1
SCHEMBL28655525 0.78 HDAC1 (0.49) PTPN1HDAC1HDAC8CES2CES1
SCHEMBL21382648 0.77 HDAC1 (0.55) PTPN1HDAC1HDAC8CES2CES1
SCHEMBL2783913 0.77 CES2 (0.56) PTPN1HDAC1HDAC8CES2CES1
SCHEMBL220588 0.76 PTPN1 (1.00) PTPN1HDAC1HDAC8CES2CES1
SCHEMBL29411099 0.76 PTPN1 (1.00) PTPN1HDAC1HDAC8CES2CES1
SCHEMBL8086233 0.76 HDAC1 (0.47) PTPN1HDAC1HDAC8CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9498476-B2 Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine ALBANY MOLECULAR RESEARCH, INC. (US) 2016-11-22 US disclosed
US-20150366864-A1 CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE CURIA GLOBAL, INC. 2015-12-24 US disclosed
US-20150191494-A1 TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR ALBANY MOLECULAR RESEARCH, INC. 2015-07-09 US disclosed
US-8445494-B2 Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine BRISTOL-MYERS SQUIBB COMPANY (US) 2013-05-21 US disclosed
US-8420811-B2 Tetrahydroisoquinolines and intermediates therefor BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-16 US disclosed
WO-2007117180-A1 AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150366864-A1 CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE HTR2C, SYNCRIP, SFPQ PTPN1 1971/4885HDAC1 259/4885HDAC8 553/4885
US-20150191494-A1 TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR FARS2, TPH1, COQ8A PTPN1 4360/4885HDAC1 560/4885HDAC8 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.